Skip to main content
Premium Trial:

Request an Annual Quote

Cellumen to Build CHDI-funded Systems Cell Biology Model of Huntington s Disease

NEW YORK, Feb.24 (GenomeWeb News) - In an agreement with non-profit CHDI, Cellumen will build a cellular model of Huntington's disease as the foundation of neurotoxicity profiling panel to characterize pre-clinical candidate models, Cellumen said yesterday.

The collaboration is expected to last about a year, Robert Pacifici of CHDI told GenomeWeb News.

"Cell-based phenotypic assays are critical for CHDI since there is not a clearly defined set of well-validated and chemically tractable targets for HD drug discovery," said Pacifici.

CHDI is the non-profit drug-discovery arm of the High Q Foundation for Huntington's disease.

Financial details were not released.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.